Diabetes, Endocrinology and Metabolism Research Group

The Academic Diabetes, Endocrinology and Metabolism Research Group (ADEM) is a team of clinical and academic researchers, led by Professor Thozhukat Sathyapalan, with expertise in diabetes, obesity, cardiovascular disease, exercise, dietetics, biochemistry, psychology and sociology.

ADEM delivers world-class research in four areas: clinical drugs trials; lifestyle research; biomedical research; and applied research. ADEM’s research findings have benefited those suffering from long-term conditions and led to significant advancement in treatment and medical knowledge. The group specialises in type 1 and 2 diabetes, metabolic syndrome, obesity, polycystic ovary syndrome, insulin resistance, non-alcoholic fatty liver disease, metabolic bone health, cardiovascular disease, and dietetics and nutrition. 

The group, which is a partnership between the Hull York Medical School and the University of Hull, is situated at Hull Royal Infirmary and the university campus. Aside from research, it also provides a range of outstanding academic postgraduate pathways and educational opportunities, including PhDs, MDs and MScs.  

ADEM’s excellent research facilities include body imaging and DEXA scanning to measures bone mineral density, dedicated laboratories, a sports science laboratory, ultrasound and access to a large pool of patients.


Head of Group

Unit Manager

  • Lisa Baldwin

Academic and research staff

  • Dr Mo Aye – Consultant Endocrinologist, Honorary Senior Lecturer
  • Dr Harshal Deshmuk – Clinical Lecturer
  • Mr James England – Consultant Endocrine Surgeon (Thyroid/parathyroid)
  • Dr David Hepburn – Clinical Dean, Hull University Teaching Hospitals NHS Trust and Honorary Reader in Diabetes, Endocrinology and Metabolism
  • Dr Deepa Narayanan – Consultant Clinical Pathologist
  • Dr Maria Papageorgiou – Advanced Research Dietician
  • Dr Sam Xu – Reader in Diabetes, Endocrinology and Metabolism


  • Dr Kamrudeen Mohammed – Consultant Endocrinologist, Honorary Senior Lecturer
  • Dr Shiva Mongolu – Consultant Endocrinologist – Honorary Lecturer

Professional support staff

  • Gill Byne – PA to Professor Sathyapalan
  • Anneli James – Research Practitioner/Project Manager
  • Dawn Lowsley – Clinical Trials Assistant
  • Lucy Newton – Clinical trials coordinator
  • Lee Rollins – Research Practitioner
  • Dana Schofield – Research Administrator
  • Zoe Sugden – Health Care Assistant
  • Carrie Willby – Clinical Trials Assistant



Disease area: Diabetes
Funder: Sanofi Aventis

A 26-week randomized, double-blind, controlled, parallel-group, multicenter study to evaluate the efficacy and safety of Sotagliflozin compared to Empagliflozin, and placebo in patients with type 2 diabetes who have inadequate glycemic control on Dipeptidyl Peptidase 4 Inhibitor (DPP4(i)) with or without Metformin


Disease area: Growth hormone deficiancy
Funder: SANDOZ

Post-Marketing Surveillance to monitor the long-term safety and efficacy of Omnitrope in the treatment of children and adults. PATROa (adults) PATROc (children).


Disease area: Type 1 diabetes
Funder: National institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the Juvenile Diabetes research Foundation and the American Diabetes Association

Natural History Study of the Development of Type 1 Diabetes. Phase 1,2 and 3.


Disease area: Type 2 diabetes
Funder: Eli Lilly and Company

The Effect of LY2189265 on Major Cardiovascular Events in Patients with Type 2 Diabetes: Reducing Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND)

Reversing PCOS

Disease area: Polycystic ovary syndrome
Funder: Hull and East Yorkshire Hospitals NHS Trust, and partially supported by Cambridge Weight company

A randomised controlled trial to investigate the effect of very low calorie diet (VLCD) versus an energy deficit approach weight loss diet, over 8 weeks, in obese women with polycystic ovarian syndrome (PCOS).

Clear Harmony

Disease area: Hypercholesterolemia
Funder: Esperion Therapeutics

A multicentre  open – lable extension (OLE) study to assess the long term safety and efficacy of Bempedoic Acid (ETC-1002) 180 MG


Disease area: Type 2 diabetes
Funder: National institute for Health research for patient benefit (RfPB)

Improving glucose control in patients with Diabetes following myocardial infarction: the role of a novel glycaemia monitoring strategy. 

Transition in Type 1 Diabetes

Disease area: Type 1 diabetes
Funder: Hull CCG

Determining the perspectives of service users and carers on the transition from adolescent to adult type 1 diabetes services within Hull and East Yorkshire, and how access/support can be improved.


Gonzalez S, Sathyapalan T, Javed Z, Atkin SL. Effects of Growth Hormone Replacement on Peripheral Muscle and Exercise Capacity in Severe Growth Hormone Deficiency. Front Endocrinol (Lausanne)2018; 9:56

Sathyapalan T, Al-Qaissi A, Kilpatrick ES, Dargham SR, Keevil B, Atkin SL. Salivary and serum androgens with anti-Mullerian hormone measurement for the diagnosis of polycystic ovary syndrome. Sci Rep2018; 8:3795

Konya J, Al Qaissi A, Sathyapalan T, Ajjan R, Madden L, Naseem KM, Garrett AT, Kilpatrick E, Atkin SL. The Effect of a Simulated Commercial Flight Environment with Hypoxia and Low Humidity on Clotting, Platelet, and Endothelial Function in Participants with Type 2 Diabetes - A Cross-over Study. Front Endocrinol (Lausanne)2018; 9:26

Chattopadhyay S, George A, John J, Sathyapalan T. Two-hour post-challenge glucose is a better predictor of adverse outcome after myocardial infarction than fasting or admission glucose in patients without diabetes. Acta Diabetol2018; 55:449-458

Papageorgiou M, Wells L, Williams C, White K, De Santis B, Liu Y, Debegnach F, Miano B, Moretti G, Greetham S, Brera C, Atkin SL, Hardie LJ, Sathyapalan T. Assessment of Urinary Deoxynivalenol Biomarkers in UK Children and Adolescents. Toxins (Basel)2018; 10

Sathyapalan T, Javed Z, Rigby AS, Kilpatrick ES, Atkin SL. Soy Protein Improves Cardiovascular Risk in Subclinical Hypothyroidism: A Randomized Double-Blinded Crossover Study. J Endocr Soc2017; 1:423-430

Sathyapalan T, Al-Qaissi A, Kilpatrick ES, Dargham SR, Atkin SL. Anti-Mullerian hormone measurement for the diagnosis of polycystic ovary syndrome. Clin Endocrinol (Oxf)2018; 88:258-262

Sathyapalan T, Aye M, Rigby AS, Fraser WD, Kilpatrick ES, Atkin SL. Effect of soy on bone turn-over markers in men with type 2 diabetes and hypogonadism - a randomised controlled study. Sci Rep2017; 7:15366

O'Doherty AF, Jones HS, Sathyapalan T, Ingle L, Carroll S. The Effects of Acute Interval Exercise and Strawberry Intake on Postprandial Lipemia. Med Sci Sports Exerc2017; 49:2315-2323

Sathyapalan T, Coady AM, Kilpatrick ES, Atkin SL. The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocr Connect2017; 6:811-816

Gonzalez S, Windram JD, Sathyapalan T, Javed Z, Clark AL, Atkin SL. Effects of human recombinant growth hormone on exercise capacity, cardiac structure, and cardiac function in patients with adult-onset growth hormone deficiency. J Int Med Res2017; 45:1708-1719

Sathyapalan T, Dickerson EH, Maguiness SM, Robinson J, Dakroury YHZ, Atkin SL. Androstenedione and testosterone levels correlate with in vitro fertilization rates in insulin-resistant women. BMJ Open Diabetes Res Care2017; 5:e000387

Dawson AJ, Kilpatrick ES, Coady AM, Elshewehy AMM, Dakroury Y, Ahmed L, Atkin SL, Sathyapalan T. Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss. BMC Endocr Disord2017; 17:41

Wells L, Hardie L, Williams C, White K, Liu Y, De Santis B, Debegnach F, Moretti G, Greetham S, Brera C, Papageorgiou M, Thatcher NJ, Rigby A, Atkin SL, Sathyapalan T. Deoxynivalenol Biomarkers in the Urine of UK Vegetarians. Toxins (Basel)2017; 9

Sathyapalan T, Al-Qaissi A, Kilpatrick ES, Dargham SR, Adaway J, Keevil B, Atkin SL. Salivary testosterone measurement in women with and without polycystic ovary syndrome. Sci Rep2017; 7:3589

Cho LW, Sathyapalan T, Kilpatrick ES, Keevil BG, Miller AG, Coady AM, Ahmed L, Atkin SL. Androsterone glucuronide to dehydroepiandrosterone sulphate ratio is discriminatory for obese Caucasian women with polycystic ovary syndrome. BMC Endocr Disord2017; 17:26

Sathyapalan T, Rigby AS, Bhasin S, Thatcher NJ, Kilpatrick ES, Atkin SL. Effect of Soy in Men With Type 2 Diabetes Mellitus and Subclinical Hypogonadism: A Randomized Controlled Study. J Clin Endocrinol Metab2017; 102:425-433

Current PhD/MD students

Mr Abayomi Sanusi - Multimorbidities in patients with diabetes and metabolic  disorders (PhD 2019-2022) (Principal Supervisor: Professor Thozhukat Sathyapalan)

Katie Bird - Evaluation of pharmacology prescribing assessment for undergraduate medical students (Principal Supervisor: Professor Thozhukat Sathyapalan)

Alexandra Macnamara - Evaluation of pharmacology teaching for undergraudate medical students (Principal Supervisor: Professor Thozhukat Sathyapalan)

Dr Mo Aye – Hull Hip fracture Intervention and Prevention Programme (HHIPP) (PhD 2015-18) OSPREY – osteoporosis research charity. (Principal Supervisor: Professor Thozhukat Sathyapalan)

Youssra HZ Dakroury - Vitamin D effects in Qatari population (MSc 2018-19), Weill Cornell at Qatar (Principal Supervisor: Professor Thozhukat Sathyapalan)

Mr REJ England - Parameters for parathyroid surgery in hyperparathyroidism (MD - 2018)

Saeed Alqarni - Endoparticle profile in patients with type 2 diabetes (PhD 2015-18) (Co-supervisor: Professor Thozhukat Sathyapalan)


The use of digital technology in patients with type 1 diabetes attending transition clinic - Hull CCG, transformation funding - £20,000. 2018

Contigency funding for research nurse - Yorkshire and Humber CRN 2017-18  £15,307

Contingency funding from CRN Yorkshire and Humber (2016-17) - £30,894 (to HEY NHS Trust)

Measurement of stress hormones in hair - HEIF funding - (2016-17) £22,500

Hull Hip Fracture Intervention and Prevention Study (HHIPS). (2017-19) – Osteoporosis Research in East Yorkshire (OSPREY), UK. - Principal Investigator. £50,000

Service users’ perspectives in accessing type 2 services within Hull. (2016-17) Yorkshire and Humber Commissioning Support, UK – Principal Investigator. £22,864

Service users’ perspectives in accessing type 2 services within East Riding of Yorkshire. (2016-17) Yorkshire and Humber Commissioning Support, UK – Principal Investigator. £9,919.00